Abstract
Introduction: Epilepsy is one of the most common neurological diseases in clinical practice. The combined application of metabolomics technology plays a great advantage in the screening of biomarkers.
Methods: In this study, Wistar rats were used as experimental subjects to model intractable epilepsy and to detect the metabolic changes of small molecules in plasma. UPLC-MS/MS was used to determine the small molecules in rat plasma. UPLC HSS C18 (2.1mm×100mm, 1.7 μm) column was used for separation, column temperature of 40°C. The initial mobile phase was acetonitrile -0.3% formic acid with gradient elution, the flow rate was 0.3 mL/min, total running time 4.0 min. Quantitative analysis was performed with multi-response monitoring (MRM).
Results: Compared to the control group, the L-Alanine and L-Arginine decreased in the Epilepsy group (p<0.05); while Cytosine, Adenosine, L-Tyrosine, Citric acid, Fructose increased (p<0.05).
Conclusion: In the screening of epilepsy biomarkers using metabolomics, various amino acids that lead to increased energy production and neurotransmitter imbalance play an important role in epileptic seizures.
Keywords: Epilepsy, plasma, UPLC-MS/MS, amino acid, rat, metabolomics.
Graphical Abstract
[http://dx.doi.org/10.1002/14651858.CD002217.pub3] [PMID: 31425629]
[http://dx.doi.org/10.1016/j.yebeh.2019.07.037] [PMID: 31398688]
[http://dx.doi.org/10.2147/RRTM.S201159] [PMID: 31388319]
[http://dx.doi.org/10.1155/2019/9130780] [PMID: 31281692]
[http://dx.doi.org/10.1097/MD.0000000000016402] [PMID: 31348240]
[http://dx.doi.org/10.1111/epi.16315] [PMID: 31423575]
[http://dx.doi.org/10.7189/jogh.07.020706] [PMID: 29302325]
[http://dx.doi.org/10.4103/0366-6999.247194] [PMID: 30539903]
[http://dx.doi.org/10.1016/j.yebeh.2018.10.001] [PMID: 30388665]
[http://dx.doi.org/10.1016/j.yebeh.2018.08.024] [PMID: 30384095]
[http://dx.doi.org/10.1016/j.seizure.2019.07.020] [PMID: 31382137]
[http://dx.doi.org/10.1016/j.seizure.2019.01.028] [PMID: 30785055]
[http://dx.doi.org/10.1177/0883073818811176] [PMID: 30484357]
[http://dx.doi.org/10.1038/s41436-018-0091-8] [PMID: 29930392]
[http://dx.doi.org/10.1016/j.eplepsyres.2019.02.001] [PMID: 30771550]
[http://dx.doi.org/10.1684/epd.2018.0959] [PMID: 29620010]
[http://dx.doi.org/10.1016/j.wneu.2018.03.145] [PMID: 29605698]
[http://dx.doi.org/10.1097/MD.0000000000016257] [PMID: 31277145]
[http://dx.doi.org/10.1016/j.seizure.2018.01.014] [PMID: 29428899]
[http://dx.doi.org/10.3389/fneur.2017.00459] [PMID: 28928712]
[http://dx.doi.org/10.1016/j.eplepsyres.2009.11.005] [PMID: 20005079]
[http://dx.doi.org/10.1111/epi.14000] [PMID: 29341105]
[http://dx.doi.org/10.1021/pr501309b] [PMID: 25761974]
[http://dx.doi.org/10.1038/s41598-019-51337-z] [PMID: 31636291]
[http://dx.doi.org/10.1039/c2mb25105a] [PMID: 22706165]
[http://dx.doi.org/10.1007/s11011-019-00424-1] [PMID: 31144103]
[http://dx.doi.org/10.1109/ACCESS.2018.2867728]
[http://dx.doi.org/10.1248/bpb.b14-00781] [PMID: 25757930]
[http://dx.doi.org/10.1155/2015/295241] [PMID: 25954748]
[PMID: 26464683]
[http://dx.doi.org/10.1002/bmc.3641] [PMID: 26525040]
[http://dx.doi.org/10.1002/bmc.3499] [PMID: 26033449]
[http://dx.doi.org/10.1556/AChrom.27.2015.1.7]
[http://dx.doi.org/10.1016/j.jpba.2015.07.031] [PMID: 26279368]
[http://dx.doi.org/10.1016/j.jchromb.2015.03.025] [PMID: 25864013]
[http://dx.doi.org/10.1021/acs.chemrestox.8b00328] [PMID: 30807114]
[http://dx.doi.org/10.1016/j.compbiolchem.2018.11.017] [PMID: 30501982]
[http://dx.doi.org/10.1556/1326.2017.00146]
[http://dx.doi.org/10.2174/1573412914666180627142952]
[http://dx.doi.org/10.1177/0748233717731959] [PMID: 28978283]
[http://dx.doi.org/10.1016/j.bbi.2019.07.014] [PMID: 31306773]
[http://dx.doi.org/10.1007/s10571-019-00685-5] [PMID: 31089833]
[http://dx.doi.org/10.1016/j.neuropharm.2019.04.028] [PMID: 31047919]
[http://dx.doi.org/10.1186/s12974-019-1414-7] [PMID: 30755225]